vs

Side-by-side financial comparison of Cipher Mining Inc. (CIFR) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

Cipher Mining Inc. is the larger business by last-quarter revenue ($59.7M vs $38.3M, roughly 1.6× ImmunityBio, Inc.). ImmunityBio, Inc. runs the higher net margin — -161.8% vs -1229.6%, a 1067.8% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 41.4%). ImmunityBio, Inc. produced more free cash flow last quarter ($-71.3M vs $-695.9M).

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

CIFR vs IBRX — Head-to-Head

Bigger by revenue
CIFR
CIFR
1.6× larger
CIFR
$59.7M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+365.5% gap
IBRX
407.0%
41.4%
CIFR
Higher net margin
IBRX
IBRX
1067.8% more per $
IBRX
-161.8%
-1229.6%
CIFR
More free cash flow
IBRX
IBRX
$624.6M more FCF
IBRX
$-71.3M
$-695.9M
CIFR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CIFR
CIFR
IBRX
IBRX
Revenue
$59.7M
$38.3M
Net Profit
$-734.2M
$-61.9M
Gross Margin
59.4%
99.0%
Operating Margin
-503.4%
-169.0%
Net Margin
-1229.6%
-161.8%
Revenue YoY
41.4%
407.0%
Net Profit YoY
-4293.1%
-4.7%
EPS (diluted)
$-1.91
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CIFR
CIFR
IBRX
IBRX
Q4 25
$59.7M
$38.3M
Q3 25
$71.7M
$32.1M
Q2 25
$43.6M
$26.4M
Q1 25
$49.0M
$16.5M
Q4 24
$42.2M
$7.6M
Q3 24
$24.1M
$6.1M
Q2 24
$36.8M
Q1 24
$48.1M
Net Profit
CIFR
CIFR
IBRX
IBRX
Q4 25
$-734.2M
$-61.9M
Q3 25
$-3.3M
$-67.3M
Q2 25
$-45.8M
$-92.6M
Q1 25
$-39.0M
$-129.6M
Q4 24
$17.5M
$-59.2M
Q3 24
$-86.8M
$-85.7M
Q2 24
$-15.3M
Q1 24
$39.9M
Gross Margin
CIFR
CIFR
IBRX
IBRX
Q4 25
59.4%
99.0%
Q3 25
62.7%
99.4%
Q2 25
64.8%
99.5%
Q1 25
69.6%
99.6%
Q4 24
56.9%
Q3 24
37.5%
Q2 24
61.2%
Q1 24
69.2%
Operating Margin
CIFR
CIFR
IBRX
IBRX
Q4 25
-503.4%
-169.0%
Q3 25
-52.5%
-173.5%
Q2 25
-103.9%
-269.8%
Q1 25
-77.8%
-390.1%
Q4 24
40.5%
-919.0%
Q3 24
-379.2%
-1314.3%
Q2 24
-43.9%
Q1 24
97.2%
Net Margin
CIFR
CIFR
IBRX
IBRX
Q4 25
-1229.6%
-161.8%
Q3 25
-4.6%
-209.8%
Q2 25
-105.1%
-350.3%
Q1 25
-79.6%
-784.9%
Q4 24
41.5%
-783.4%
Q3 24
-359.9%
-1404.0%
Q2 24
-41.5%
Q1 24
82.9%
EPS (diluted)
CIFR
CIFR
IBRX
IBRX
Q4 25
$-1.91
$-0.06
Q3 25
$-0.01
$-0.07
Q2 25
$-0.12
$-0.10
Q1 25
$-0.11
$-0.15
Q4 24
$0.04
$-0.08
Q3 24
$-0.26
$-0.14
Q2 24
$-0.05
Q1 24
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CIFR
CIFR
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$628.3M
$242.8M
Total DebtLower is stronger
$2.7B
Stockholders' EquityBook value
$805.5M
$-500.5M
Total Assets
$4.3B
$501.9M
Debt / EquityLower = less leverage
3.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CIFR
CIFR
IBRX
IBRX
Q4 25
$628.3M
$242.8M
Q3 25
$1.2B
$257.8M
Q2 25
$62.7M
$153.7M
Q1 25
$23.2M
$61.6M
Q4 24
$5.6M
$149.8M
Q3 24
$25.3M
$130.4M
Q2 24
$122.6M
Q1 24
$88.7M
Total Debt
CIFR
CIFR
IBRX
IBRX
Q4 25
$2.7B
Q3 25
$1.0B
Q2 25
$167.1M
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CIFR
CIFR
IBRX
IBRX
Q4 25
$805.5M
$-500.5M
Q3 25
$783.2M
$-524.3M
Q2 25
$748.9M
$-570.7M
Q1 25
$734.8M
$-591.4M
Q4 24
$682.0M
$-489.1M
Q3 24
$672.0M
$-745.1M
Q2 24
$690.8M
Q1 24
$600.9M
Total Assets
CIFR
CIFR
IBRX
IBRX
Q4 25
$4.3B
$501.9M
Q3 25
$2.8B
$519.0M
Q2 25
$1.0B
$402.1M
Q1 25
$913.8M
$303.8M
Q4 24
$855.4M
$382.9M
Q3 24
$775.4M
$364.6M
Q2 24
$775.6M
Q1 24
$677.1M
Debt / Equity
CIFR
CIFR
IBRX
IBRX
Q4 25
3.37×
Q3 25
1.31×
Q2 25
0.22×
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CIFR
CIFR
IBRX
IBRX
Operating Cash FlowLast quarter
$-207.9M
$-70.4M
Free Cash FlowOCF − Capex
$-695.9M
$-71.3M
FCF MarginFCF / Revenue
-1165.4%
-186.2%
Capex IntensityCapex / Revenue
817.1%
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.1B
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CIFR
CIFR
IBRX
IBRX
Q4 25
$-207.9M
$-70.4M
Q3 25
$-50.1M
$-68.9M
Q2 25
$-56.2M
$-79.7M
Q1 25
$-47.2M
$-85.9M
Q4 24
$-87.5M
$-85.1M
Q3 24
$-6.5M
$-98.8M
Q2 24
$-25.4M
Q1 24
$-26.6M
Free Cash Flow
CIFR
CIFR
IBRX
IBRX
Q4 25
$-695.9M
$-71.3M
Q3 25
$-256.2M
$-69.6M
Q2 25
$-87.5M
$-80.8M
Q1 25
$-71.8M
$-87.0M
Q4 24
$-227.0M
$-87.3M
Q3 24
$-83.2M
$-101.6M
Q2 24
$-33.2M
Q1 24
$-34.5M
FCF Margin
CIFR
CIFR
IBRX
IBRX
Q4 25
-1165.4%
-186.2%
Q3 25
-357.3%
-217.2%
Q2 25
-200.9%
-305.9%
Q1 25
-146.7%
-526.9%
Q4 24
-537.6%
-1155.4%
Q3 24
-345.0%
-1663.2%
Q2 24
-90.2%
Q1 24
-71.7%
Capex Intensity
CIFR
CIFR
IBRX
IBRX
Q4 25
817.1%
2.4%
Q3 25
287.5%
2.3%
Q2 25
71.8%
4.1%
Q1 25
50.2%
6.8%
Q4 24
330.4%
28.0%
Q3 24
317.8%
45.7%
Q2 24
21.4%
Q1 24
16.4%
Cash Conversion
CIFR
CIFR
IBRX
IBRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-5.00×
Q3 24
Q2 24
Q1 24
-0.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons